Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Oct 1.

Published in final edited form as: Invest New Drugs. 2022 Jun 27;40(5):1087–1094. doi: 10.1007/s10637-022-01276-w

Table 2.

Most Frequent Treatment Emergent Adverse Events

Toxicity	Patients, N (%)
	ASP1650 1,000mg/m² (N=6)	ASP1650 1,500mg/m² (N=13)	Total (N=19)	Grade≥3
Anemia	3 (50)	3 (23.1)	6 (31.6)	6 (31.6)
Abdominal Pain	1 (16.7)	2 (15.4)	3 (15.8)	2 (10.5)
Nausea	2 (33.3)	1 (7.7)	3 (15.8)	1 (5.2)
Vomiting	3 (50%)	0	3 (15.8)	1 (5.2)
Decreased appetite	2 (33.3)	1 (7.7)	3 (15.8)	1 (5.2)
Anxiety	2 (33.3)	1 (7.7)	3 (15.8)	0
Diarrhea	0	2 (15.4)	2 (10.5)	0
Fatigue	2 (33.3)	0	2 (10.5)	0
Peripheral edema	1 (16.7)	1 (7.7)	2 (10.5)	0
Increased serum creatinine	1 (16.7)	1 (7.7)	2 (10.5)	0
Arthralgia	0	2 (15.4)	2 (10.5)	0
Insomnia	1 (16.7)	1 (7.7)	2 (10.5)	0
Dyspnea	1 (16.7)	1 (7.7)	2 (10.5)	0
Rash	0	2 (15.4)	2 (10.5)	0